Sign in
Taking people in NetherlandsPhase 1

Study of how brensocatib and midazolam affect each other in the body

Tests how brensocatib and midazolam interact in adults with non-cystic fibrosis bronchiectasis.

Key facts

Who runs it
Insmed Inc.
Where
Groningen, NetherlandsSee the site
Registry title
Drug-drug interaction study of midazolam and brensocatib
Status
Recruiting
Phase
Phase 1
People taking part
26 people, planned
Started
6 Oct 2026
Planned end
5 Nov 2026
Type of study
Interventional
Record updated
10 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults aged 18 to 64 to study how midazolam and brensocatib act together. The condition listed is non-cystic fibrosis bronchiectasis.

Age
18 to 64 years
Sex
All sexes can join.

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 64 years old?

Where in Netherlands

  • Pharmaceutical Research Associates Group B.V.Groningen, NetherlandsTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Plain-language title
Study of how brensocatib and midazolam affect each other in the bodyGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 11 November 2026.
Fit questions
Built from 2026-526670-16-00, who can take part
Record updated
10 November 2026